Is Anavar Safer Only On Training Days?
Timeline
Timestamp
Topic
00:00
Dr. O’Connor introduces the practice of adding Anavar to testosterone only on training days and examines whether reducing cumulative exposure may lessen cardiovascular, kidney, liver, and other health risks.
01:50
The presentation reviews legitimate medical uses of oxandrolone, including severe burns and muscle wasting, and emphasizes that published studies generally involve much smaller doses than those commonly used for physique enhancement.
07:10
Dr. O’Connor describes the anecdotal practice of using lower-dose Anavar only two or three times weekly on training days while stressing that no clinical trials prove this approach is safe.
12:40
The discussion turns to blood pressure and dyslipidemia, with Dr. O’Connor explaining that Anavar and other anabolic steroids can raise blood pressure, increase LDL, and reduce HDL in a dose-dependent manner.
16:00
Dr. O’Connor examines liver risk, explaining that Anavar may be less hepatotoxic than some other oral anabolic steroids but can still raise liver enzymes when doses exceed those studied medically.
21:20
The final section focuses on kidney injury, proteinuria, and focal segmental glomerulosclerosis, including why normal creatinine or estimated GFR can miss early disease and why urine testing and cystatin C may provide important additional information.
Video Summary
Men on testosterone often ask whether limiting Anavar to training days can reduce its health risks. Dr. O’Connor examines the limited evidence behind this harm-reduction approach and distinguishes established medical oxandrolone research from anecdotal use by men combining Anavar with testosterone.
He explains that medical studies have generally used relatively small oxandrolone doses for conditions such as severe burns and muscle wasting, while bodybuilding doses can be substantially higher. Although intermittent use may reduce cumulative exposure, Dr. O’Connor stresses that there are no clinical trials proving that taking Anavar only on training days makes recreational use safe.
The presentation focuses on blood pressure, dyslipidemia, liver enzymes, and kidney injury, including proteinuria and focal segmental glomerulosclerosis. Dr. O’Connor emphasizes monitoring blood pressure, lipids, liver markers, creatinine, cystatin C, urinalysis, and urine albumin while reducing unnecessary androgen exposure and protecting long-term cardiovascular and kidney health.
Drug Callouts
Drug
Description
Anavar (Oxandrolone)
Oxandrolone is the central anabolic steroid discussed and is compared across legitimate low-dose medical use and higher-dose physique-oriented use. Dr. O’Connor explains that limiting Anavar to training days may reduce cumulative exposure, but no clinical evidence establishes this practice as safe.
Testosterone
The presentation specifically addresses mature men already using testosterone who consider adding Anavar intermittently. Dr. O’Connor emphasizes that combining testosterone with another anabolic steroid increases total androgen exposure and requires attention to cardiovascular, kidney, liver, and metabolic risk.
Telmisartan
Telmisartan is discussed near the kidney-protection section as an angiotensin receptor blocker that may be used when appropriate for blood-pressure and renal management. Dr. O’Connor places blood-pressure control among the most important protective measures for men with anabolic steroid-related kidney risk.
Jardiance (Empagliflozin)
Jardiance is discussed as an SGLT2 inhibitor with evidence supporting kidney and cardiovascular protection in appropriate patients. Dr. O’Connor raises this drug class while discussing early kidney disease and the need for medically supervised treatment rather than relying only on stopping steroids.
Farxiga (Dapagliflozin)
Farxiga is discussed alongside Jardiance as an SGLT2 inhibitor that may have renal and cardiovascular benefits in selected patients. Dr. O’Connor emphasizes that these medications require appropriate medical evaluation and are not substitutes for reducing harmful androgen exposure.
Condition Callouts
Condition
Description
Hypertension
Dr. O’Connor describes elevated blood pressure as a common dose-dependent consequence of Anavar and other anabolic steroids. Men already using testosterone may compound cardiovascular and kidney stress when additional androgens further increase blood pressure.
Dyslipidemia
Anavar can adversely affect cholesterol by increasing LDL and reducing HDL, even during relatively short periods of use. Dr. O’Connor emphasizes that men combining oxandrolone with testosterone should evaluate lipid changes while actually using the drugs rather than only after discontinuation.
Drug-Induced Liver Injury
Oxandrolone is described as comparatively less hepatotoxic than some other 17-alpha-alkylated steroids but still capable of raising liver enzymes at higher doses. Dr. O’Connor emphasizes distinguishing exercise-related AST elevation from true hepatic injury using the broader laboratory and clinical picture.
Focal Segmental Glomerulosclerosis
Dr. O’Connor discusses focal segmental glomerulosclerosis as a serious form of kidney injury he has observed in anabolic steroid users. Continued testosterone and anabolic steroid exposure may worsen underlying glomerular stress, particularly when hypertension and proteinuria are already present.
Proteinuria
Protein leakage into the urine may appear before creatinine or estimated GFR becomes abnormal in men with anabolic steroid-related kidney injury. Dr. O’Connor emphasizes urinalysis and urine albumin-to-creatinine testing because normal blood kidney markers do not necessarily exclude early disease.
Key Takeaways
- There are no clinical trials proving that taking Anavar only on training days makes its use safe.
- Medical oxandrolone studies generally involve substantially smaller doses than those commonly used for bodybuilding or physique enhancement.
- Even intermittent Anavar use can raise blood pressure and adversely affect LDL and HDL cholesterol.
- Anavar may be less hepatotoxic than some oral anabolic steroids but can still raise liver enzymes when exposure becomes excessive.
- Normal creatinine and estimated GFR can miss early anabolic steroid-related kidney injury when proteinuria is already present.
- Reducing cumulative androgen exposure while monitoring blood pressure, lipids, liver markers, urine protein, and kidney function is central to harm reduction.